Anthracycline Cardiotoxicity in Adult Cancer Patients: <i>JACC: CardioOncology</i> State-of-the-Art Review.

ABSTRACT: Since their introduction in the 1960s, anthracyclines have been a significant breakthrough in oncology, introducing dramatic changes in the treatment of solid and hematologic malignancies. Although new-generation targeted drugs and cellular therapies are revolutionizing contemporary oncology, anthracyclines remain the cornerstone of treatment for lymphomas, acute leukemias, and soft tissue sarcomas. However, their clinical application is limited by a dose-dependent cardiotoxicity that can reduce cardiac performance and eventually lead to overt heart failure. The field of cardio-oncology has emerged to safeguard the cardiovascular health of cancer patients receiving these therapies. It focuses on controlling risk factors, implementing preventive strategies, ensuring appropriate surveillance

SUBMITTER: Camilli M 

PROVIDER: S-EPMC11520218 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature